News
NVS
151.72
-0.39%
-0.60
Immunome: Maintaining My 'Strong Buy' Rating With 2 Catalysts On The Horizon
Seeking Alpha · 9h ago
Roche Is Getting More Benefit Of The Doubt On Improving Execution
Seeking Alpha · 11h ago
Pharma companies sour on Swiss drug applications amid Trump’s MFN policy
Seeking Alpha · 12h ago
SCHD vs. VYMI vs. VIG: Which Is the Best Dividend ETF for Passive Income Investors?
TipRanks · 1d ago
3 Vanguard Dividend ETFs to Boost Passive Income
TipRanks · 3d ago
Noteworthy ETF Outflows: AVSD, HSBC, NVS, MUFG
NASDAQ · 3d ago
Weekly Report: what happened at NVS last week (0803-0807)?
Weekly Report · 3d ago
Novartis Might Struggle to Clear Bar in Cholesterol Drug Trial -- Market Talk
Dow Jones · 3d ago
J.P. Morgan Keeps Their Buy Rating on Novartis AG (NOVN)
TipRanks · 3d ago
Weekly Buzz: MRNA, NVS, SNY Gain Approvals; EBS, LSTA Cut Jobs; TARS, BIVI Drive Deals & Data
NASDAQ · 6d ago
Novartis India Approves Termination Of Distribution Agreement With Dr. Reddy’s Laboratories; Termination Agreement With Dr. Reddy’s Effective September 30, 2026; To Re-Buy Exclusivity And Market Access For Products After DRL Agreement Termination
Benzinga · 6d ago
Roche upgraded at Morgan Stanley on growth, pipeline upside
Seeking Alpha · 6d ago
Amgen: The Market Is Underestimating Its Next Growth Phase
Seeking Alpha · 6d ago
These New Drugs Could Fuel Fresh Highs for Biotech and Pharma Stocks
Barron‘s · 6d ago
These New Drugs Could Fuel Fresh Highs for -2-
Barron‘s · 6d ago
Novartis gains UK approval of Rhapsido for urticaria
Seeking Alpha · 08/06 17:25
MHRA Approves Remibrutinib For Adults With Chronic Spontaneous Urticaria
Benzinga · 08/06 15:11
Teva Pharmaceuticals: Continuing To Execute On Its 'Pivot To Growth' Plan
Seeking Alpha · 08/05 20:05
Amgen: First $10 Billion Quarter, More Growth Ahead
Seeking Alpha · 08/05 18:21
Amgen price target raised to $351 from $333 at Morgan Stanley
TipRanks · 08/05 11:41
More
Webull provides a variety of real-time NVS stock news. You can receive the latest news about Novartis through multiple platforms. This information may help you make smarter investment decisions.
About NVS
Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.